Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance

Akt is a pro‐survival kinase frequently activated in human cancers and is associated with more aggressive tumors that resist therapy. Here, we connect Akt pathway activation to reduced sensitivity to chemotherapy via Akt phosphorylation of Bax at residue S184, one of the pro‐apoptotic Bcl‐2 family proteins required for cells to undergo apoptosis. We show that phosphorylation by Akt converts the pro‐apoptotic protein Bax into an anti‐apoptotic protein. Mechanistically, we show that phosphorylation (i) enables Bax binding to pro‐apoptotic BH3 proteins in solution, and (ii) prevents Bax inserting into mitochondria. Together, these alterations promote resistance to apoptotic stimuli by sequestering pro‐apoptotic activator BH3 proteins. Bax phosphorylation correlates with cellular resistance to BH3 mimetics in primary ovarian cancer cells. Further, analysis of the TCGA database reveals that 98% of cancer patients with increased BAX levels also have an upregulated Akt pathway, compared to 47% of patients with unchanged or decreased BAX levels. These results suggest that in patients, increased phosphorylated anti‐apoptotic Bax promotes resistance of cancer cells to inherent and drug‐induced apoptosis.

[1]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death. , 2018 .

[2]  M. Sousa,et al.  Regulation of Bax/mitochondria interaction by AKT , 2016, FEBS letters.

[3]  S. Mazumder,et al.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies , 2015, Cell Death and Disease.

[4]  D. Haussler,et al.  Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser , 2013, Scientific Reports.

[5]  A. Berger,et al.  ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis , 2013, Cell Death and Disease.

[6]  D. Andrews,et al.  tBid Undergoes Multiple Conformational Changes at the Membrane Required for Bax Activation* , 2013, The Journal of Biological Chemistry.

[7]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[8]  D. Andrews,et al.  Mechanisms of action of Bcl-2 family proteins. , 2013, Cold Spring Harbor perspectives in biology.

[9]  M. Kalmanti,et al.  Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features , 2013, Genetics and molecular biology.

[10]  E. Åvall Lundqvist,et al.  Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites , 2012, BMC Cancer.

[11]  F. D. De Braud,et al.  Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. , 2012, Translational oncology.

[12]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[13]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[14]  D. Green,et al.  A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.

[15]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[16]  M. Davidson,et al.  An Improved Cerulean Fluorescent Protein with Enhanced Brightness and Reduced Reversible Photoswitching , 2011, PloS one.

[17]  W. Curran,et al.  Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax , 2010, PloS one.

[18]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[19]  Seamus J. Martin,et al.  Expression, purification and use of recombinant annexin V for the detection of apoptotic cells , 2009, Nature Protocols.

[20]  A. Waxman,et al.  IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[21]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[22]  D. Andrews,et al.  Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax , 2008, Cell.

[23]  D. Andrews,et al.  Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax , 2008, PLoS biology.

[24]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[25]  A. Letai,et al.  Regulation of Bcl-2 family proteins by posttranslational modifications. , 2008, Current molecular medicine.

[26]  T. Hunter,et al.  Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition , 2007, Oncogene.

[27]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[28]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[29]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[30]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[31]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[32]  D. Andrews,et al.  Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis , 2005, The EMBO journal.

[33]  Yan Shi,et al.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo , 2005, Molecular Cancer Therapeutics.

[34]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK control multiple initiator caspases , 2005, EMBO reports.

[35]  Xingming Deng,et al.  Nicotine Inactivation of the Proapoptotic Function of Bax through Phosphorylation* , 2005, Journal of Biological Chemistry.

[36]  S. Wang,et al.  Phosphorylation of Bad is not essential for PKB-mediated survival signaling in hemopoietic cells , 2005, Apoptosis.

[37]  D. Danielpour,et al.  Overexpression of Bax sensitizes prostate cancer cells to TGF-β induced apoptosis , 2005, Cell Research.

[38]  David A Hildeman,et al.  ×Phosphorylation of Bax Ser184 by Akt Regulates Its Activity and Apoptosis in Neutrophils* , 2004, Journal of Biological Chemistry.

[39]  Patrick Dumont,et al.  Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex , 2004, Nature Cell Biology.

[40]  S. R. Datta,et al.  Bad-deficient mice develop diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[42]  H. Friess,et al.  Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents , 2002, Cancer Chemotherapy and Pharmacology.

[43]  H. Yamaguchi,et al.  The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change , 2001, Oncogene.

[44]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[45]  J. Foekens,et al.  Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 , 2001, British Journal of Cancer.

[46]  E. Kandel,et al.  Akt/Protein Kinase B Inhibits Cell Death by Preventing the Release of Cytochrome c from Mitochondria , 1999, Molecular and Cellular Biology.

[47]  Y. Hsu,et al.  Conformation of the Bax C‐terminus regulates subcellular location and cell death , 1999, The EMBO journal.

[48]  A. Hall,et al.  Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. , 1999, Blood.

[49]  S. Cannistra,et al.  BAX protein expression and clinical outcome in epithelial ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T Takahashi,et al.  Overexpression of bax sensitizes human breast cancer MCF‐7 cells to radiation‐induced apoptosis , 1996, International journal of cancer.

[51]  B. Dörken,et al.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. , 1996, The Journal of clinical investigation.

[52]  K. Franssila,et al.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. , 1995, Cancer research.

[53]  AML , 2019, Springer Reference Medizin.

[54]  D. Andrews,et al.  Examining the molecular mechanism of bcl-2 family proteins at membranes by fluorescence spectroscopy. , 2014, Methods in enzymology.

[55]  C. Sakakura,et al.  Overexpression ofBax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide , 2006, Surgery Today.

[56]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[57]  D. Hasenclever,et al.  High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML) , 2002, Leukemia.